Search
EHA-SWG Scientific Meeting on Integrated Cell Tracking in Oncohematology: Diagnosis, Targeted Therapy and Residual Disease
Dates: November 10-12, 2022
Location: Bordeaux, France
Format: Hybrid
Chair: MC Béné
Registration has closed
This was the third time EHA is collaborating with the EHA Specialized Working Group on Diagnosis in hematological diseases, to bring you the latest in laboratory hematology.…
1st EHA-Balkan Hematology Day
EHA is joining forces with the national societies from the Balkan countries and co-organizing with them the 1st edition of the EHA-Balkan Hematology Day.
Read moreGdf -11 a new target to improve anemia in thalassemia.
β-thalassemias are characterized by ineffective red blood cell (RBC) production, leading to anemia, iron overload, and organ failure. As current treatment options for β-thalassemia are limited, there is a clear unmet need for alternative therapies.
EHA Congratulates EHA Kick-Off Grant 2022 Winners
The Hague, December 8, 2022 – EHA Congratulates seven talented researchers in Hematology on their receipt of an EHA Kick-Off Grant 2022 after a rigorous selection process.
Read moreEHA in EU-funded project on voluntary plasma collection capacity in Europe
EHA to participate in an EU-funded project on “Strengthening voluntary non-remunerated plasma collection capacity in Europe” (SUPPLY)
Context: Plasma shortage
Plasma-derived medicinal products (PDMPs) are used to treat a variety of rare, chronic, and potentially life-threatening conditions including immune deficiencies, immune-mediated peripheral…
Publications
Cellular therapies in older adults with hematological malignancies: A case-based, state-of-the-art review
Neuendorff NR, Khan A, Ullrich F, Yates S, Devarakonda S, Lin RJ, von Tresckow B, Cordoba R, Artz A, Rosko AE. J Geriatr Oncol. 2024 Feb 29;15(3):101734.
Publications
Dexamethasone treatment for COVID-19 is related to increased mortality in hematologic malignancy patients: results from the EPICOVIDEHA registry
Aiello TF, Salmanton-Garcia J, Marchesi F, et al. Haematologica. 2024 Aug 1;109(8):2693-2700.
Evaluation of 243 patients with deletion 17p chronic lymphocytic leukemia treated with ibrutinib: a cross-study analysis of treatment outcomes
Evaluation of 243 patients with deletion 17p chronic lymphocytic leukemia treated with ibrutinib: a cross-study analysis of treatment outcomes
Chronic lymphocytic leukemia (CLL) with the deletion of chromosome 17p (del17p) has been linked to aggressive disease and patient survival of only…
Immunotherapy delivered by Blinatumomab improves survival in acute lymphoblastic leukaemia patients
Adult patients with acute lymphoblastic leukemia (ALL) can achieve disease control in 90% of cases with intense chemotherapy but only half of these responders will be cured.
Read moreMeeting program
Thursday, April 18*All times are in EET. 16:00 - 19:00 EET Satellite symposia
Novartis
Hoffman-La Roche
Takeda
Various satellite symposia will take place the day before the meeting for national and regional participants.
- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- »